Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes

Basit Öğe Kaydı
dc.contributor.authorKerimoglu, Ozlem Secilmis
dc.contributor.authorErcan, Cihangir Mutlu
dc.contributor.authorKeskin, Ugur
dc.contributor.authorKorkmaz, Cem
dc.contributor.authorDuru, Namik Kemal
dc.contributor.authorErgun, Ali
dc.date.accessioned2020-03-26T18:41:35Z
dc.date.available2020-03-26T18:41:35Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThis study aims to determine whether a low dose of the gonadotropin releasing hormone antagonist, cetrorelix, prevents a premature luteinizing hormone (LH) surge and affects in vitro fertilization (IVF) outcomes compared to the standard dose of 0.25 mg/day. In this study, 45 IVF/intracytoplasmic sperm injection patients were stimulated with recombinant follicle stimulation hormone from day 2 of the cycle. Cetrorelix was injected daily from day 6 of gonadotropin administration. Twenty-two patients received cetrorelix at a dose of 0.25 mg/day, whereas 23 participants received half dose. The mean consumption of gonadotropins was significantly higher in patients receiving 0.25 mg/day of cetrorelix (2,213 vs. 1,350 U; p = 0.046). The clinical pregnancy rates were similar in both groups (31.8 vs. 47.8 %; p = 0.273). Premature LH surge was detected in 9.1 % of the patients receiving cetrorelix 0.25 mg/day and in 13 % of the patients receiving cetrorelix 0.125 mg/day (p > 0.05). The difference between two groups was not statistically significant (p > 0.05). Our results suggest that there is no difference between a cetrorelix dose of 0.125 or 0.25 mg/day in preventing premature LH rise during ovarian stimulation for IVF.en_US
dc.identifier.doi10.1007/s00404-013-2806-zen_US
dc.identifier.endpage695en_US
dc.identifier.issn0932-0067en_US
dc.identifier.issue3en_US
dc.identifier.pmid23525593en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage691en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s00404-013-2806-z
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29404
dc.identifier.volume288en_US
dc.identifier.wosWOS:000323212900034en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGER HEIDELBERGen_US
dc.relation.ispartofARCHIVES OF GYNECOLOGY AND OBSTETRICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAntagonisten_US
dc.subjectCetrorelixen_US
dc.subjectIn vitro fertilizationen_US
dc.subjectLH surgeen_US
dc.titleEffect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu